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PHM8
THE POTENTIAL IMPACT OF CHELATION THERAPY (CT) ON
THE QUALITY OF LIFE (QOL) OF PATIENTS WITH IRON
OVERLOAD (IO)
Abetz L1, Jones P2, Baladi JF2
1Mapi Values, Macclesﬁeld, Cheshire, UK; 2Novartis Pharmaceutical
Corporation, East Hanover, PA, USA
OBJECTIVES: Repeated blood transfusions can result in IO and
lead to life-threatening complications in patients with sickle cell
disease (SCD), thallasaemia (TLA) or myelodysplastic syndrome
(MDS). The most common IO CT, Desferal (DFO), requires infu-
sions of 8–12 hours, 5–7 days per week, potentially limiting QoL
and inhibiting adherence. METHODS: A literature review (539
abstracts; 130 articles), analysis of four IO patient transcripts
(one MDS, one SCDA, two TLA) and interviews with three IO
experts were conducted to assess the potential impact of CT on
patients’ lives. RESULTS: Results suggested the signiﬁcant neg-
ative impact of CT with DFO on patient QoL, particularly social
life, self-image, intimate relationships, emotional well-being,
pain and sleep, though very few published studies (15) measured
this impact with validated QoL instruments. No IO or CT-spe-
ciﬁc QoL instruments were found. Published articles and
patient/clinician input suggested a need for easier, efﬁcacious and
safe oral IO treatments, given the impact of current CT on QoL
inhibits adherence. CONCLUSION: Limited empirical studies
assessed the impact of CT or IO on QoL, though all reviewed
articles stated that CT’s QoL impact is signiﬁcant and would
improve with oral therapy. However, the impacted QoL domains
may differ by age, condition, and how long CT has been used.
It is recommended to continue both the qualitative and the quan-
titative study of QoL in chelated patients in patients with MDS,
SCD, and TLA using validated instruments in order to further
our understanding of the issues and improve patient’s quality of
life.
PHM9
HOW PATIENTS WITH HAEMOPHILIA ARE SATISFIED WITH
THEIR TREATMENT
Von Mackensen S1, Scalone L2, Mantovani LG2, Gringeri A3
1Institute for Medical Psychology, Hamburg, Germany; 2Center of
Pharmacoeconomy, Milan, Italy; 3Haemophilia and Thrombosis Centre,
Milan, Italy
OBJECTIVES: Treatment of patients with haemophilia, a 
congenital bleeding disorder, treated with repeated infusions of
clotting factor concentrates, requires a substantial amount of
economical and human resources and therefore it is mandatory
to investigate treatment satisfaction of haemophilic patients.
Purpose of this study was to evaluate patients’ experience of dif-
ferent treatment regimens and to validate the newly developed
haemophilia-speciﬁc treatment satisfaction scale for adults
(Hemo-SatA) in the COCHE Study (Cost of Care of Hemophilia
Study). METHODS: 233 adult haemophilia patients without
inhibitors from 23 Italian Haemophilia Centers were enrolled in
the naturalistic, multicenter, longitudinal COCHE Study. Treat-
ment satisfaction was assessed with the Hemo-SatA, which con-
sists of 34 items pertaining to 6 domains (ease & convenience,
efﬁcacy, burden, specialist, centre, general). RESULTS: Mean age
of patients was 37 years. Around one-third of the patients
received prophylactic treatment (n = 75) and most of them were
treated with recombinant products (58.8%). In general patients
were satisﬁed with their treatment. Patients were mostly unsat-
isﬁed in the dimensions “ease & convenience” and “efﬁcacy”;
42% worried about the risk of inhibitors associated with their
medication and 14% were unsatisﬁed with the number of infu-
sions that are needed to stop a bleeding. Signiﬁcant differences
in treatment satisfaction (Hemo-SatA) were found for socio-
demographic data concerning marital status and age groups
(“burden”); separated persons were more unsatisﬁed with their
treatment (“specialist”, “general satisfaction”, “Total Hemo-
Sat”).Signiﬁcant differences were found as well for clinical data
concerning ‘treatment type’, ‘type of haemophilia’ and ‘target
joints’; patients with more than 1 target joint were more un-
satisﬁed (“efﬁcacy”). Psychometric characteristics of the pilot
testing of the Hemo-SatA could be conﬁrmed in the COCHE
Study. CONCLUSIONS: Results could conﬁrm that treatment
satisfaction is an important outcome criterion in the treatment
of patients with chronic diseases. Hemo-SatA proved to be a
valid and reliable instrument assessing.
NEUROLOGICAL DISORDERS
PNL1
EXTERNAL VALIDATION OF THE PROBABILISTIC MARKOV
MODEL ESTIMATING THE COST EFFECTIVENESS OF
MEMANTINE VERSUS STANDARD CARE IN ALZHEIMER
DISEASE FROM A UK PERSPECTIVE
Guilhaume C1, Rive B2, Francois C1, Livingston G3, Katona C4
1Lundbeck SA, Paris, France; 2Altipharm SA, Paris, France; 3University
College London, London, UK; 4University of Kent, Canterbury, UK
A Markov model was developed to estimate the cost effective-
ness of memantine compared with no pharmacological treatment
in British AD patients with MMSE £14 over a 2-year period. It
simulated a patient’s progression through series of health stages
combining different level of severity, dependency and setting of
care. Transition probabilities for the model were computed on
the basis of the data from the LASER-AD cohort (London and
the Southeast Region Alzheimer’s Disease) over six months, and
were then extrapolated using the Markov assumption to simu-
late the long-term course of disease. Since then the LASER-AD
has been extended and now 18 months data follow up are avail-
able. OBJECTIVE: To validate the model externally by compar-
ing the results extrapolated in the model with those observed in
the LASER-AD cohort at 18 months. METHOD: A Markov
cohort analysis was conducted on the model in order to compute
the percentages of patients in the different health stages at all
cycles using the distribution at baseline of the LASER-AD. The
analysis was conducted on the “standard care” treatment strat-
egy only, and was stopped at the third cycle (18 months). Per-
centages from the model were compared with those obtained
from the LASER-AD study after having observed 95 patients
with a baseline MMSE £14. RESULTS: Based on model analy-
ses, after 18 months 84.5% of patients are severe, 87.8% are
dependent and 71.5% are institutionalized (versus respectively
83.8%, 90.3% and 73.3% in the LASER-AD). The difference
between the two estimates is greatest for mortality (respectively
40.6% versus 31.6%). CONCLUSION: It is rare to have the
opportunity to validate a pharmacoeconomic model externally.
These analyses show very similar estimates of the disease course
between the memantine UK pharmacoeconomic model and the
‘real’ long-term data from the LASER-AD cohort. This strength-
ens the modeling approach used.
PNL2
COST-EFFECTIVENESS OF ADDING MEMANTINE TREATMENT
TO PATIENTS RECEIVING STABILISED DOSES OF DONEPEZIL
IN THE UK
Guilhaume C1, Rive B2, Cochran J1
1Lundbeck SA, Paris, France; 2Altipharm SA, Paris, France
OBJECTIVES: Assess the cost-effectiveness in a UK setting 
of providing memantine treatment to moderate to severe
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Alzheimer’s disease (AD) in patients receiving stable donepezil
treatment compared with not providing memantine.
METHODS: Data from a U.S. multicenter randomised clinical
trial that compared memantine versus placebo in moderate to
severe AD patients on stable doses of donepezil was used to eval-
uate the cost effectiveness of providing memantine to donepezil.
Using methodology developed by Kurz et al., patients were clas-
siﬁed at each visit as dependent or non-dependent according to
their ADCS-ADL19 scores. Mean weekly costs were estimated
from the National Health Service and Personal Social Services
perspectives for patients with MMSE £14 that participated in a
UK epidemiological study—the LASER-AD study. QALYs per
dependency were estimated from a Danish Study. Per week mean
acquisition cost and effectiveness of treatment were £975;
0.6511 and £288; 0.3207 for dependent and non-dependent
patients. Total drug costs for the 24-week period were £492 for
donepezil and £937 for memantine plus donepezil. Costs,
QALYs and time of non-dependence were associated with each
dependency level and added to obtain total outcomes over the
24-week study period. RESULTS: Over the evaluation period,
memantine added to patients stabilised on donepezil was 
associated with an additional 0.0112 QALYs, an additional 
1.77 weeks of independence and a £771 cost reduction compared
with donepezil alone. The cost reduction is not statistically sig-
niﬁcant but suggests that clinical advantages offset some of the
cost of adding memantine. CONCLUSION: This analysis sug-
gests that memantine treatment provided to patients receiving
stable donepezil treatment is cost-effective compared with not
adding memantine. As costs and QALYs were assessed retro-
spectively, further prospective studies are required to support this
ﬁnding.
PNL3
RETROSPECTIVE COMPARATIVE ANALYSIS OF
ANTIDEMENTIA MEDICATION PERSISTENCE PATTERNS AT 3
YEARS IN SPANISH ALZHEIMER DISEASE PATIENTS TREATED
WITH DONEPEZIL, RIVASTIGMINE, GALANTAMINE AND
MEMANTINE
Sicras A1,Vergara J2, León T3, Febrer L4, Rejas J3
1Badalona Servicios Asistenciales, SA, Badalona, Barcelona, Spain;
2Health Center, Benahadux, Almería, Spain; 3Pﬁzer Spain, Alcobendas,
Madrid, Spain; 4SALUTIS RESEARCH, S.L, Barcelona, Barcelona, Spain
OBJECTIVE: To determine persistence of treatment with
donepezil (DON), rivastigmine (RIV), galantamine (GAL) and
memantine (MEM) in patients with Alzheimer Dementia (AD)
in a Spanish population setting. METHODS: Retrospective AD
cohort study performed in nine Primary Care Health Centers
from four different Autonomous Communities (Andalucia,
Cantabria, Cataluña & Valencia) in Spain. Descriptive standard
analyses were performed. ANOVA and Chi-square tests were
used to show the differences among mean duration therapy and
treatment adherence after 52 weeks. A Kaplan-Meier survival
analysis was applied to assess overall pattern persistence after
three-year of follow up, and the log rank test was used for testing
signiﬁcance. RESULTS: A total of 299 patients (44.8% female),
mean age 77.88 years (SD: 6.32), were included; 101 DON
(34%), 105 RIV (35%), 51 GAL (17%) and 42 MEM (14%).
Mean treatment duration was slightly longer and signiﬁcant for
DON patients 83.3 weeks (95% CI: 72.7–93.9) than for the
other drugs: RIV; 76.6 (66.0–87.3), GAL; 65.8 (55.3–76.3),
MEM; 60.9 (48.8–73.1), p = 0.049. Treatment adherence after
52 weeks was numerically higher with DON (63%) than with
the other medications: RIV; 55%, GAL; 55%, and MEM; 52%,
p = 0.525. Overall persistence of treatment was signiﬁcantly
higher with DON [median time; 70.3 weeks (95% CI:
49.8–90.7)] than for the others drugs: RIV [56.1 weeks
(36.1–76.2)], GAL [56.7 weeks (41.1–72.3)] and MEM [52.1
weeks (35.2–69.1)], Log Rank = 10.16, p = 0.017. CONCLU-
SION: This retrospective study including Spanish AD patients
showed numerically differences on treatment adherence after one
year of therapy among the four antidementia medications com-
mercially available. The global treatment persistence during the
three-year follow up was signiﬁcantly higher in patients treated
with donepezil compared to those who received rivastigmine,
galantamine or memantine.
PNL4
THE SOCIAL AND ECONOMIC BURDEN OF PAEDIATRIC
EPILEPSY IN IRELAND: A PROSPECTIVE STUDY
McGinn M1, Najam Y2, Deiratany S2, Grant D3, Sawyer W3,
Reeves P3, Hughes J4,Webb D1, McMenamin J1
1Our Lady’s Hospital for Sick Children, Crumlin, Dublin, Ireland; 2Royal
College of Surgeons in Ireland, Dublin, Dublin County, Ireland; 3Fourth
Hurdle Consulting Ltd, London, UK; 4GlaxoSmithKline Ireland, Dublin,
Ireland
OBJECTIVE: To estimate the overall burden of pediatric
epilepsy on the family and Irish health care system and to estab-
lish whether there is a relationship between epilepsy proﬁle and
this burden. METHOD: The sample was drawn from a popula-
tion of children with epilepsy attending a tertiary pediatric neu-
rology clinic in Dublin. Data was collected prospectively on
health care resource use and time lost from school and work.
Diary cards were completed at three monthly intervals.
RESULTS: Complete data was available on 127 children aged
15 months to 16.7 years (median 8.8), 54% were male and 52%
lived in a rural setting. A total of 61% had cryptogenic or symp-
tomatic epilepsy, 63% had partial seizures and 53% had frequent
seizures (>10 seizures/month). The annual cost of epilepsy was
signiﬁcantly higher for those with cryptogenic/symptomatic
epilepsy (€9248) and frequent seizures (€9145) relative to idio-
pathic epilepsy (€2600) and no/infrequent seizures (€3951) (P <
0.0001). Children with frequent seizures had a higher risk of
being hospitalised (P = 0.03) and lost more days at school (P <
0.0005). 50% of families contacted the pediatric liaison nurse,
and 12% made more than 5 contacts. Five percent of children
attended their GP while 37% of families had independently
sought complementary medicine. CONCLUSIONS: The eco-
nomic and social burden of pediatric epilepsy is substantial and
relates to the epilepsy syndrome and frequency of seizures. In
this prospective study a large dependence on epilepsy liaison
nurse support was found, an area that requires extra resources.
A large number of families also sought advice from non medical
sources.
PNL5
A PROSPECTIVE STUDY ON THE IMPACT OF A CHILD’S
EPILEPSY ON THEIR QUALITY OF LIFE AND THEIR FAMILY
Deiratany S1, Najam Y1, Grant D2, Sawyer W2, Hughes J3,
McMenamin J4,Webb D4, Reeves P2
1Royal College of Surgeons in Ireland, Dublin, Dublin County, Ireland;
2Fourth Hurdle Consulting Ltd, London, UK; 3GlaxoSmithKline Ireland,
Dublin, Ireland; 4Our Lady’s Hospital for Sick Children, Crumlin,
Dublin, Ireland
OBJECTIVES: The aim of this prospective study was to deter-
mine the relationship between seizure type, seizure frequency and
epilepsy syndrome on the quality of life of both the child and
family over a one year period. METHOD: The sample was
drawn from a population of children with epilepsy attending a
tertiary Paediatric Neurology service in Dublin. Data was col-
lected on seizure type and frequency, epilepsy syndrome, physi-
